Who We Are
Formed as a joint venture between Advanced Cell Technology, a leading U.S.-based stem cell research company and CHA Bio & Diostech Co., Ltd., a leading Korea-based biotechnology company, SCRMI is harnessing expertise from both sides of the globe in order to drive our cutting-edge stem cell research endeavors. With laboratories located in Marlborough, Massachusetts, USA and scientific advisers from across the continents, SCRMI is committed to advancing the field of regenerative medicine.
What We Do
Research at SCRMI is focused on differentiating human embryonic stem cells and induced pluripotent stem cells into 2 main therapeutic cell types: (1) transfusable blood components and (2) vascular repair cells. Both of these research areas take advantage of our unique hemangioblast and iPS cell technologies during the differentiation process from stem cell to therapeutic cell of interest.